EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Safety and Efficacy of Long‐Term Treatment of Type 1 Plasminogen Deficient Patients With Intravenous Plasminogen Replacement Therapy

Amy D Shapiro iD, Heather McDaniel, Robert W Decker, Charles Nakar iD, Jeremy Lorber iD, Neelam Thukral, Joseph M Parker, Karen Thibaudeau iD

Haemophilia · 2025

DOI: 10.1111/hae.70019 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Haemophilia, 2025. Verfasst von Amy D Shapiro und 7 weiteren Autor:innen. Beteiligte Einrichtung: Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Blood Coagulation Disorders, Inherited, Plasminogen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kedrion Biopharma, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Type 1 plasminogen deficiency (PLGD‐1), or hypoplasminogenaemia, is an ultra‐rare autosomal‐recessive disorder characterised by fibrin‐rich lesions on mucous membranes, often leading to serious complications if left untreated. Prior treatments have shown limited and inconsistent success, but IV PLG concentrate (Ryplazim) offers a targeted therapy.

Aim

This study investigated the long‐term safety and efficacy of IV PLG concentrate treatment for PLGD‐1 patients.

Methods

A long‐term study (NCT03642691) followed 12 participants who had previously been included in pivotal or expanded access trials of IV PLG concentrate. Participants received 6.6 mg/kg IV PLG concentrate infusions, with dosing frequency adjusted based on clinical response and plasminogen levels. Safety assessments and plasminogen level measurements were conducted.

Results

The median treatment duration during this long‐term follow‐up study was 41 months (range: 25–42 months). The median total exposure for participants in this study throughout the clinical development was 68 months (range: 28–71 months). No new or recurring ligneous lesions occurred when participants adhered to the prescribed regimen. Temporary disruptions in the drug supply led to some lesion recurrences, which resolved upon resuming the prescribed dosing frequency. A total of 2165 infusions were administered in this study, and most adverse events were mild. No anti‐plasminogen antibodies or treatment‐related fatalities occurred.

Conclusion

Long‐term treatment with IV PLG concentrate is safe and effective for PLGD‐1, demonstrating the potential for tailored dosing regimens. This study highlights the importance of individualised treatment and provides valuable insights into managing this ultra‐rare disorder.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood Coagulation Disorders, InheritedPlasminogenAdolescentAdultChildFemaleHumansMaleMiddle AgedYoung AdultTreatment OutcomeConjunctivitisSkin Diseases, Genetic

Stichwörter der Autor:innen

hypoplasminogenaemialigneous conjunctivitisligneous lesionsplasminogenplasminogen deficiency type 1plasminogen replacement therapypseudomembranes

Substanzen

Plasminogen

Autor:innen und Institutionen

  • Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, USA.
  • Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Consultant to Kedrion Biopharma, Fort Lee, New Jersey, USA.
  • Global Medical Affairs, Kedrion S.p.A, Laval, Quebec, Canada.

ORCID-Profile: Amy D Shapiro, Charles Nakar, Jeremy Lorber, Karen Thibaudeau

Förderung

  • Kedrion Biopharma, Inc.

Zitieren

APA

Shapiro, A. D., McDaniel, H., Decker, R. W., Nakar, C., Lorber, J., Thukral, N., Parker, J. M., & Thibaudeau, K. (2025). Safety and Efficacy of Long‐Term Treatment of Type 1 Plasminogen Deficient Patients With Intravenous Plasminogen Replacement Therapy. Haemophilia. https://doi.org/10.1111/hae.70019

Vancouver

Shapiro AD, McDaniel H, Decker RW, Nakar C, Lorber J, Thukral N, et al. Safety and Efficacy of Long‐Term Treatment of Type 1 Plasminogen Deficient Patients With Intravenous Plasminogen Replacement Therapy. Haemophilia. 2025. doi:10.1111/hae.70019

BibTeX
@article{Shapiro2025,
  author = {Shapiro, Amy D and McDaniel, Heather and Decker, Robert W and Nakar, Charles and Lorber, Jeremy and Thukral, Neelam and Parker, Joseph M and Thibaudeau, Karen},
  title = {Safety and Efficacy of Long‐Term Treatment of Type 1 Plasminogen Deficient Patients With Intravenous Plasminogen Replacement Therapy},
  journal = {Haemophilia},
  year = {2025},
  doi = {10.1111/hae.70019}
}
Kostenlos starten →